Phase I, first-in-human trial of BI 836826 (an anti-CD37 antibody) in patients (PTS) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)
2015
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI